The original success of the copyright undeniably transformed the pharmaceutical landscape, but investing in companies primarily reliant on unbranded versions presents a uncertain picture. Despite early earnings were substantial, the cessation of patents and the emergence of less expensive alternatives have eroded market share. Thus, a thorough asse